Llagas, Rizelda .

HRN: 21-89-81  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/20/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/20/2022
09/27/2022
IV
500 Mg
Q8
Prom Msaf
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Intervention



Type of Intervention done:

                    

           


Acceptance: